The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
The $100 billion partnership between dominant AI chipmaker Nvidia and leading artificial intelligence company OpenAI could give both companies an unfair advantage over their competitors, experts say.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback